Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars
06 déc. 2022 07h00 HE
|
Jeito Capital
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars Ce nouveau tour de table permettra d’accélérer le développement clinique et...
Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing
06 déc. 2022 07h00 HE
|
Jeito Capital
Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing The Series C extension round will...
Jeito Capital affirme son leadership dans le secteur biopharmaceutique européen avec la cession de Neogene Therapeutics à AstraZeneca
29 nov. 2022 02h22 HE
|
Jeito Capital
Jeito Capital affirme son leadership dans le secteur biopharmaceutique européen avec la cession de Neogene Therapeutics à AstraZeneca ...
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics
29 nov. 2022 02h19 HE
|
Jeito Capital
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics Deal...
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
22 nov. 2022 05h00 HE
|
Jeito Capital
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients...
Jeito Capital investit dans CatalYm Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie
22 nov. 2022 05h00 HE
|
Jeito Capital
Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie Jeito Capital co-dirige un financement de série C de 50 millions d'euros avec Brandon...
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies auto-immunes
01 nov. 2022 09h05 HE
|
Jeito Capital
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies...
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
01 nov. 2022 06h02 HE
|
Jeito Capital
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with...
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix
16 mars 2022 03h00 HE
|
Jeito Capital
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision...
Jeito Capital co-leads $65 million Series A financing in EyeBio
22 févr. 2022 05h01 HE
|
Jeito Capital
Jeito Capital co-leads $65 million Series A financing in EyeBio EyeBio is a newly launched global company developing the next generation of eye disease therapiesFounded by two pioneers in...